biotech
AbbVie
Sponsor view across the ADC target screen, including linked targets and source-linked trial evidence.
ADC target activity
Tracked targets
| Target | Trial count | Evidence |
|---|---|---|
| FRα / FOLR1 / Folate receptor alpha | 4 | Source |
| c-MET / MET | 1 | Source |
| PTK7 | 1 | Source |
Linked trials
Clinical evidence links
- NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (COMPLETED)
- NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (ACTIVE_NOT_RECRUITING)
- NCT04189614: An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (TERMINATED)
- NCT06890338: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (RECRUITING)
- NCT06682988: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine (RECRUITING)
- NCT02099058: A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (ACTIVE_NOT_RECRUITING)